Placeholder

What’s on Your Mind — Opinions

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 48. Category: .

Product Description

Registering Results: A Public Database of Clinical-Trial Information
Consumer groups, professional medical associations, and medical journals are calling for public disclosure of all medical studies and for drug manufacturers to register their clinical trials in a public database once the trials begin. PharmaVOICE asked: Should companies have to register their clinical trials as they are initiated in a public database?

Opinion Responses:

Great Concept Carlos Chua, Senior Clinical Research Associate, Organon Pharmaceuticals USA Inc.

Collective Best Interest
George D’Addamio, Ph.D., President, PharmConsult Inc.

A Valuable Resource
Stephen Ruger, Project Manager, 21 CFR Part 11 Validation

An Idea With Merit
Philip Lavin, Ph.D., President, Averion Inc.

Full Disclosure
Peter T. Kissinger, Ph.D., Chairman and CEO, Bioanalytical Systems Inc.

Just Say No
Cathy Mojzisik, RN, MS, Blackburn International Inc.

Take Extreme Care
Howard L. Golub, M.D., Ph.D., President , CareStat Inc.

A Number of Positives
James M. Mash, President, International Pharmaceutical Development LLC

Critical to Research
Marion Stamp-Cole, Senior Director Clinical Research, ProMed Healthcare Research Division

Little Value to Consumers
Paula Wilkerson, RAC. Director, Regulatory Affairs, Applied Genetic Technologies Corp.

Voluntary, Not Mandatory
Bill Hahn, VP, Marketing & Business Development, Shaw Science Partners Inc.

Across The Board
Aleecia A. Quinn, Clinical Trials Specialist, Henry Jackson Foundation

Appeasing the Critics
Betsy Payne Watson, Independent Clinical Consultant, BPW Consulting LLC

In Support, After Trials
Michael Simmons, Clinical Data Manager, Human Genome Sciences Inc.

FEEDBACK